VEGFA and head and neck squamous cell carcinoma: In terms of VEGF secretion, the majority of the HNSCC cases treated with either pembrolizumab or pembrolizumab plus cetuximab (both 16/23) demonstrated positive effects, whereas such effects were observed in only 8 of the 23 samples treated with cetuximab alone.